SET domain-containing 5 is a potential prognostic biomarker that promotes esophageal squamous cell carcinoma stemness.


Journal

Experimental cell research
ISSN: 1090-2422
Titre abrégé: Exp Cell Res
Pays: United States
ID NLM: 0373226

Informations de publication

Date de publication:
01 04 2020
Historique:
received: 21 11 2019
revised: 20 01 2020
accepted: 21 01 2020
pubmed: 26 1 2020
medline: 18 11 2020
entrez: 26 1 2020
Statut: ppublish

Résumé

SET domain-containing 5 (SETD5) is an uncharacterized member of the protein lysine methyltransferase family. Although it was reported that SETD5 gene mutations are associated with the several types of human cancer, its functional role in esophageal squamous cell carcinoma (ESCC) progression has not been fully elucidated. In the present study, we used tissue samples from 147 patients with ESCC and ESCC cell lines to determine the clinicopathological significance of SETD5 in ESCC and its effects on ESCC stemness. We performed immunohistochemical staining, immunofluorescence imaging, and tumor sphere formation, colony formation, flow cytometry, wound healing, Transwell, and western blotting assays. SETD5 expression was upregulated in ESCC tissue and associated with primary tumor (pT) stage, clinical stage, lymph node metastasis, shorter overall survival rate, and disease-free survival rate. Cox regression analyses indicated that SETD5 is an independent poor prognostic factor of ESCC. In addition, SETD5 expression was correlated with cancer stemness-related protein, hypoxia-inducible factor-1α (HIF-1α), and CD68 expression. Moreover, immunofluorescence analysis revealed that SETD5 was co-localized with CD44 and SOX2 in TE10 and TE11 cells and that exposing cells to cobalt chloride increased HIF-1α, SETD5, and stemness-related protein expression in a time-dependent manner. Furthermore, SETD5 expression was significantly correlated with the expression of cell cycle-related genes and PI3K/Akt signaling pathway-related proteins. Finally, knocking down SETD5 downregulated the expression of stemness-related and PI3K/Akt signaling pathway proteins, while inhibiting tumor spheroid formation, cell proliferation, migration, and invasion in ESCC cells. These results indicate that SETD5 expression is associated with cancer stemness and that SETD5 is a potential prognostic biomarker and therapeutic target for ESCC.

Identifiants

pubmed: 31981592
pii: S0014-4827(20)30055-0
doi: 10.1016/j.yexcr.2020.111861
pii:
doi:

Substances chimiques

Biomarkers, Tumor 0
RNA, Small Interfering 0
Methyltransferases EC 2.1.1.-
SETD5 protein, human EC 2.1.1.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

111861

Informations de copyright

Copyright © 2020. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors state that they have no conflicts of interest.

Auteurs

Lihua Piao (L)

Institute for Regenerative Medicine, Yanbian University College of Medicine, Yanji, 133002, Jilin Province, PR China.

Haoyue Li (H)

Institute for Regenerative Medicine, Yanbian University College of Medicine, Yanji, 133002, Jilin Province, PR China; Department of Pathology, Yanbian University College of Medicine, Yanji, 133002, Jilin Province, PR China.

Ying Feng (Y)

Institute for Regenerative Medicine, Yanbian University College of Medicine, Yanji, 133002, Jilin Province, PR China; Department of Pathology, Yanbian University College of Medicine, Yanji, 133002, Jilin Province, PR China.

Zhaoting Yang (Z)

Institute for Regenerative Medicine, Yanbian University College of Medicine, Yanji, 133002, Jilin Province, PR China; Department of Pathology, Yanbian University College of Medicine, Yanji, 133002, Jilin Province, PR China.

Seokhyung Kim (S)

Department of Pathology, Samsung Medical Center, Sungkyunkwan University College of Medicine, Seoul, 110-745, South Korea.

Yanhua Xuan (Y)

Institute for Regenerative Medicine, Yanbian University College of Medicine, Yanji, 133002, Jilin Province, PR China; Department of Pathology, Yanbian University College of Medicine, Yanji, 133002, Jilin Province, PR China. Electronic address: xuanyh1@ybu.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH